Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Sulindac tablets		Polyhydramnios (women only)
Sunitinib capsules	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA) TA169 - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma TA179 - Sunitinib for the treatment of gastrointestinal stromal tumours TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	Hospital use only
Supplementary preparations (Addiphos)
Supplementary preparations (Additrace)
Supplementary preparations (Peditrace)
Supplementary preparations (Solivito N)
Supplementary preparations (Vitlipid N)
Suxamethonium injection
Symtuza®
Tacrolimus 0.1% w/w in OrabaseTM		Unlicensed special

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.